Immune therapy of non-small cell lung cancer. the future

Pharmacological Research

Volumn 99, Issue , 2015, Pages 217-222

  Bobbio, Antonio ^a   Alifano, Marco ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Adjuvant; Immune checkpoint; Immunotherapy; Lung cancer; PD 1; PDL 1

Indexed keywords

MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; LUNG NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; INFLAMMATION; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84936866781     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.06.011     Document Type: Article

References (65)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER stat fact sheets: lung and bronchus cancer (http://www.seer.cancer.gov/statfacts/html/lungb.html).
2. S.S. Devesa, F. Bray, and A.P. Vizcaino International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising Int. J. Cancer 117 2005 294 299
3. A. Belot, P. Grosclaude, and N. Bossard Cancer incidence and mortality in France over the period 1980-2005 Rev. Epidemiol. Sante Publique 56 2008 159 175
4. C. Allemani, H.K. Weir, and H. Carreira Global surveillance of cancer survival 1995-2009 analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet 385 2015 977 1010 10.1016/S0140-6736(14)62038-9
5. P.A. Wingo, L.A. Ries, and G.A. Giovino Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking J. Natl. Cancer Inst. 91 1999 675 690
6. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N. Engl. J. Med. 355 2006 2542 2550
7. P. Jha, C. Ramasundarahettige, and V. Landsman 21st-century hazards of smoking and benefits of cessation in the United States N. Engl. J. Med. 368 2013 341 350 10.1056/NEJMsa1211128
8. J. Chin, T. Syrek Jensen, and L. Ashby Screening for lung cancer with low-dose CT - translating science into Medicare coverage policy N. Engl. J. Med. 372 2015 2083 2085 10.1056/NEJMp1502598
9. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
10. S. Gettinger, and T. Lynch A decade of advances in treatment for advanced non-small cell lung cancer Clin. Chest Med. 32 2011 839 851 10.1016/j.ccm.2011.08.017
11. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674 10.1016/j.cell.2011.02.013
12. K. Chansky, J.P. Sculier, J.J. Crowley International Staging Committee and Participating Institutions The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer J. Thorac. Oncol. 4 2009 792 801
13. R. Rami-Porta, V. Bolejack, and P. Goldstraw The new tumor, node, and metastasis staging system Semin. Respir. Crit. Care Med. 32 2011 44 51
14. P. Goldstraw New staging system: how does it affect our practice? J. Clin. Oncol. 31 2013 984 991
15. R. Rami-Porta, V. Bolejack, D.J. Giroux International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee. Advisory Board Members and Participating Institutions. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer J. Thorac. Oncol. 9 2014 1618 1624
16. S. Strano, A. Lupo, and F. Lococo Prognostic significance of vascular and lymphatic emboli in resected pulmonary adenocarcinoma Ann. Thorac. Surg. 95 2013 1204 1210
17. A. Kiliçgün, A. Turna, and A. Sayar Very important histopathological factors in patients with resected non-small cell lung cancer: necrosis and perineural invasion Thorac. Cardiovasc. Surg. 58 2010 93 97
18. A. Mansuet-Lupo, A. Bobbio, and H. Blons The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort Chest 146 2014 633 643
19. N. Guibert, M. Ilie, and E. Long KRAS mutations in lung adenocarcinoma: molecular and epidemiological characteristics, methods for detection, and therapeutic strategy perspectives Curr. Mol. Med. May (5) 2015 (Epub ahead of print)
20. R. Stahel, J. Bogaerts, and F. Ciardiello Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development Cancer Treat. Rev. 41 2015 129 135
21. M. Sonobe, M. Nakagawa, and K. Takenaka Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer J. Surg. Oncol. 95 January (1) 2007 63 69
22. M. Wu, J. Zhao, and S.W. Song EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer Lung Cancer 67 2010 343 347
23. J.L. Guan, W.Z. Zhong, and S.J. An KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy Ann. Surg. Oncol. 20 2013 1381 1388
24. L. Wang, H. Hu, and Y. Pan PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup PLOS ONE 9 2014 e88291
25. M. Sun, X.H. Liu, and K.M. Wang Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition Mol. Cancer 13 2014 68
26. Q. Xia, Z. Zhu, and J. Wang Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer Tumour Biol. 33 2012 1719 1725
27. M. Alifano, F. Souazé, and S. Dupouy Neurotensin receptor 1 determines the outcome of non-small cell lung cancer Clin. Cancer Res. 16 2010 4401 4410
28. M. Younes, Z. Wu, and S. Dupouy Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib Oncotarget 5 2014 8252 8269
29. K. Takahashi, C. Furukawa, and A. Takano The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer Cancer Res. 66 2006 9408 9419
30. B. Nisman, N. Heching, H. Biran, V. Barak, and T. Peretz The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer Tumour Biol. 27 1 2006 8 16
31. M. Alifano, G. Benedetti, and R. Trisolini Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer? An urgent call for research Chest 126 2004 601 607
32. G.Y. Ku, B.A. Haaland, and G. de Lima Lopes Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials Lung Cancer 74 2011 469 473
33. A.T. Shaw, D.W. Kim, K. Nakagawa, T. Seto, L. Crinó, M.J. Ahn, T. De Pas, B. Besse, B.J. Solomon, F. Blackhall, Y.L. Wu, M. Thomas, K.J. O'Byrne, D. Moro-Sibilot, D.R. Camidge, T. Mok, V. Hirsh, G.J. Riely, S. Iyer, V. Tassell, A. Polli, K.D. Wilner, and P.A. Jänne Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N. Engl. J. Med. 368 June (25) 2013 2385 2394
34. Intergroup Trial UNICANCER UC 0105-1305/IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients (SAFIR02-Lung). Available at: www.clinicaltrials.gov.
35. G. Lazennec, and A. Richmond Chemokines and chemokine receptors: new insights into cancer-related inflammation Trends Mol. Med. 16 2010 133 144
36. M.S. Shiels, R.M. Pfeiffer, and A. Hildesheim Circulating inflammation markers and prospective risk for lung cancer J. Natl. Cancer Inst. 105 2013 1871 1880
37. K.H. Allin, S.E. Bojesen, and B.G. Nordestgaard Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer J. Clin. Oncol. 13 2009 2217 2224
38. M. Alifano, P.E. Falcoz, and V. Seegers Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer J. Thorac. Cardiovasc. Surg. 142 2011 1161 1167
39. A. Koch, H. Fohlin, and S. Sorenson Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy J. Thorac. Oncol. 4 2009 326 332
40. J.G. Lee, B.C. Cho, and M.K. Bae Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer Lung Cancer 63 2009 106 110
41. M. Hara, Y. Matsuzaki, and T. Shimuzu Preoperative serum C-reactive protein level in non-small cell lung cancer Anticancer Res. 27 2007 3001 3004
42. M. Alifano, A. Mansuet-Lupo, and F. Lococo Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer PLOS ONE 9 2014 e106914 10.1371/journal.pone.0106914
43. W.H. Fridman, F. Pages, and C. Sautes-Fridman The immune contexture in human tumours: impact on clinical outcome Nat. Rev. Cancer 12 2012 298 306
44. R. Remark, M. Alifano, and I. Cremer Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin Clin. Cancer Res. 19 2013 4079 4091
45. J. Goc, C. Germain, and T.K. Vo-Bourgais Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells Cancer Res. 74 2014 705 715
46. R.K. Chandra Nutrition and the immune system: an introduction Am. J. Clin. Nutr. 66 1997 460 463
47. J.M. Chemnitz, R.V. Parry, and K.E. Nichols SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation J. Immunol. 173 2004 945 950
48. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 2012 2455 2465
49. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 2012 2443 2454
50. E.B. Garon, N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M.J. Ahn, E. Felip, J.S. Lee, M.D. Hellmann, O. Hamid, J.W. Goldman, J.C. Soria, M. Dolled-Filhart, R.Z. Rutledge, J. Zhang, J.K. Lunceford, R. Rangwala, G.M. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi KEYNOTE-001 Investigators Pembrolizumab for the treatment of non-small-cell lung cancer N. Engl. J. Med. 372 May (21) 2015 2018 2028
51. S.N. Gettinger, L. Horn, and L. Gandhi Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J. Clin. Oncol. April (20) 2015 pii:JCO.2014.58.3708
52. J. Brahmer, K.L. Reckamp, and P. Baas Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N. Engl. J. Med. May (31) 2015 (Epub ahead of print)
53. H.A. Wakelee, J.H. Schiller, and D.R. Gandara Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial Clin. Lung Cancer 8 2006 18 21
54. R. Arriagada, B. Bergman, A. Dunant International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N. Engl. J. Med. 350 2004 351 360
55. R. Arriagada, A. Dunant, and J.P. Pignon Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer J. Clin. Oncol. 28 2010 35 42
56. K. Kelly, N.K. Altorki, and W.E.E. Eberhardt A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results J. Clin. Oncol. 32 2014 5
57. J. Vansteenkiste, M. Zielinski, and A. Linder Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results J. Clin. Oncol. 31 2013 2396 2403
58. J.F. Vansteenkiste, B. Cho, and T. Vanakesa MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer Ann. Oncol. 25 2014 409 416
59. BR31 trial: Double Blind Placebo Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC. Accessible at: www.clinicaltrials.gov.
60. M. Ilie, V. Hofman, E. Long-Mira, E. Selva, J.M. Vignaud, B. Padovani, J. Mouroux, C.H. Marquette, and P. Hofman "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease PLOS ONE 9 October (10) 2014 e111597
61. V. Hofman, M. Ilie, and E. Long Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls Curr. Mol. Med. 14 2014 440 456
62. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
63. P.J. Barnes, and B.R. Celli Systemic manifestations and comorbidities of COPD Eur. Respir. J. 33 2009 1165 1185
64. M.L. Moy, M. Teylan, and N.A. Weston Daily step count is associated with plasma C-reactive protein and IL-6 in a US cohort with COPD Chest 145 2014 542 550 10.1378/chest.13-1052
65. K. Sugawara, H. Takahashi, and C. Kasai Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD Respir. Med. 104 2010 1883 1889